In preclinical models of NB, BET inhibitors such as JQ1, a novel thienotriazolo-1,4-diazepine, have been demonstrated to downregulate MYC expression by displacing BET bromodomains from chromatin after selectively recognizing and competitively binding histone acetylated lysine residues [5, 6]. Here, MYC is linked to neuroblastoma.